Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

被引：44

作者：

Abrahamsson, Anna ^{[1
]}

Dahle, Nina ^{[1
]}

Jerkeman, Mats ^{[1
]}

机构：

[1] Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden

来源：

LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 10期

关键词：

Mantle cell lymphoma; population; Swedish Lymphoma Registry; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; IMMUNOCHEMOTHERAPY;

D O I：

10.3109/10428194.2011.587560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7-0.9) for patients diagnosed during the latest time period, 20062010, also when corrected for prognostic factors as above. Estimated OS at 3 years was 62%, compared to 47% for patients diagnosed earlier (p < 0.01). The reasons for this dramatic improvement in OS are not yet clear, but may be due to the introduction of specific and more potent therapeutic regimens.

引用

页码：1929 / 1935

页数：7

共 9 条

[1] New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].

Armitage, JO ;

Weisenburger, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795

[2] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[3] Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group [J].

Geisler, Christian H. ;

Kolstad, Arne ;

Laurell, Anna ;

Andersen, Niels S. ;

Pedersen, Lone B. ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Nordstrom, Marie ;

Kimby, Eva ;

Boesen, Anne Marie ;

Kuittinen, Outi ;

Lauritzsen, Grete F. ;

Nilsson-Ehle, Herman ;

Ralfkiaer, Elisabeth ;

Akerman, Mans ;

Ehinger, Mats ;

Sundstrom, Christer ;

Langholm, Ruth ;

Delabie, Jan ;

Karjalainen-Lindsberg, Marja-Liisa ;

Brown, Peter ;

Elonen, Erkki .

BLOOD, 2008, 112 (07) :2687-2693

[4]

Hermine O., 2010, BLOOD, V116, P110, DOI [10.1182/blood.v116.21.110.110, DOI 10.1182/BLOOD.V116.21.110.110]

[5] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG) [J].

Lenz, G ;

Dreyling, M ;

Hoster, E ;

Wörmann, B ;

Dührsen, U ;

Metzner, B ;

Eimermacher, H ;

Neubauer, A ;

Wandt, H ;

Steinhauer, H ;

Martin, S ;

Heidemann, E ;

Aldaoud, A ;

Parwaresch, R ;

Hasford, J ;

Unterhalt, M ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1984-1992

[6] The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma [J].

Rosenwald, A ;

Wright, G ;

Wiestner, A ;

Chan, WC ;

Connors, JM ;

Campo, E ;

Gascoyne, RD ;

Grogan, TM ;

Muller-Hermelink, HK ;

Smeland, EB ;

Chiorazzi, M ;

Giltnane, JM ;

Hurt, EM ;

Zhao, H ;

Averett, L ;

Henrickson, S ;

Yang, LM ;

Powell, J ;

Wilson, WH ;

Jaffe, ES ;

Simon, R ;

Klausner, RD ;

Montserrat, E ;

Bosch, F ;

Greiner, TC ;

Weisenburger, DD ;

Sanger, WG ;

Dave, BJ ;

Lynch, JC ;

Vose, J ;

Armitage, JO ;

Fisher, RI ;

Miller, TP ;

LeBlanc, M ;

Ott, G ;

Kvaloy, S ;

Holte, H ;

Delabie, J ;

Staudt, LM .

CANCER CELL, 2003, 3 (02) :185-197

[7]

RUMMEL M, 2009, BLOOD S1, V114

[8] Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting [J].

van de Schans, Saskia A. M. ;

Janssen-Heijnen, Maryska L. G. ;

Nijziel, Marten R. ;

Steyerberg, Ewout W. ;

van Spronsen, Dick Johan .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09) :1503-1509

[9] Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 [J].

Zhou, Yuhong ;

Wang, Haijun ;

Fang, Wenjing ;

Romaguer, Jorge E. ;

Zhang, Yanxia ;

Delasalle, Kay B. ;

Kwak, Larry ;

Yi, Oing ;

Du, Xianglin L. ;

Wang, Michael .

CANCER, 2008, 113 (04) :791-798

← 1 →